Potential neuroprotective therapy for glaucomatous optic neuropathy

Survey of Ophthalmology

Volumn 42, Issue 4, 1998, Pages 367-372

  Yoles, Eti ^a   Schwartz, Michal ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Glaucoma; Neuroprotection; Optic nerve injury

Indexed keywords

ANTIHYPERTENSIVE AGENT; DEXANABINOL; DIZOCILPINE; EXCITATORY AMINO ACID; FREE RADICAL; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GROWTH FACTOR; N METHYL DEXTRO ASPARTIC ACID; NEUROTRANSMITTER; POTASSIUM ION;

ARTICLE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; OPTIC NERVE LESION; PRIORITY JOURNAL; VISUAL IMPAIRMENT;

EID: 0031890633     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(97)00123-9     Document Type: Review

References (39)

1. Armaly MF, Krueger DE, Maunder Let al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defect. Arch Ophthalmol. 98:1980;2163-2171.
2. Assia E, Rosner M, Belkin M, Schwartz M Temporal parameters and low-energy laser irradiation for optimal delay of posttraumatic degeneration of rat optic nerve. Brain Res. 476:1989;205-212.
3. Brubaker RF Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol. 121:1996;473-483.
4. Bullock R Strategies for neuroprotection with glutamate antagonists. Ann NY Acad Sci. 765:1995;272-278.
5. Caprioli J Correlation of visual function with optic nerve and nerve fiber layer structure in glaucoma. Surv Ophthalmol. 33(Suppl):1989;319-330.
6. Choi DA Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
7. Choi DW The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci. 13:1990;171-182.
8. Crowe MJ, Bresnahan JC, Shuman SLet al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 3:1997;73-76.
9. Danysz W, Parsons CG, Bresnick I, Quack G Glutamate in CNS disorders. Drug News Perspectives. 8:1995;261-277.
10. Doble A Excitatory amino acid receptors and neurodegeneration. Therapie. 50:1995;319-337.
11. Dreyer EB, Zurakowski D, Schumer RAet al. Elevated glutamate levels in the vitrebody of humans and monkeys with glaucoma. Arch Ophthalmol. 114:1996;299-305.
12. Duvdevani R, Rosner M, Belkin Met al. Graded crush of the rat optic nerve as a brain injury model. combining electrophysiological and behavioral outcome Restor Neurol Neurosci. 2:1990;31-38.
13. Eitan S, Solomon A, Lavie Vet al. Recovery of visual response of injured adult rat optic nerves treated with transglutaminase. Science. 264:1994;1764-1768.
14. Faden AI Pharmacotherapy in spinal cord injury. a critical review of recent developments Clin Neuropharmacol. 10:1987;193-204.
15. Faden AI, Salzman S Pharmacological strategies in CNS trauma. Trends Pharmacol Sci. 13:1992;29-35.
16. Fechtner RD, Weinreb RN Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol. 39:1994;23-42.
17. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 61:1995;33-44.
18. Jones KA, Baughman RW Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture. Neuron. 7:1991;593-603.
19. Kitazawa Y, Horie T, Aoki Set al. Untreated ocular hypertension. Arch Ophthalmol. 95:1977;1180-1184.
20. Leske MC The epidemiology of open-angle glaucoma. a review Am J Epidemiol. 118:1983;166-191.
21. Liu D, Yang R, Yan X, McAdoo DJ Hydroxyl radicals generated in vivo kill neurons in the rat spinal cord. Electrophysiological, histological, and neurochemical results J Neurochem. 62:1994;37-44.
22. Lynch DR, Dawson TM Secondary mechanisms in neuronal trauma. Curr Opin Neurol. 7:1994;510-516.
23. McIntosh TK Novel pharmacologic therapies in the treatment of experimental traumatic brain injury. A review J Neurotrauma. 10:1993;15-61.
24. Muir KW, Lees KR Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
25. Perkins ES The Bedford glaucoma survey. I. Long-term follow-up of borderline cases. Br J Ophthalmol. 57:1975;179-185.
26. Povlishock JT, Christman CW The pathobiology of traumatically induced axonal injury in animals and humans. A review of current thoughts J Neurotrauma. 12:1995;555-564.
27. Quigley HA, Addicks EM, Green WR, Maumenee AE Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Am J Ophthalmol. 99:1981;635-649.
28. Quigley HA, Nickells RW, Kerrigan LAet al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 36:1995;774-786.
29. Ransom BR, Waxman SG, Davis PK Anoxic injury of CNS white matter. Protective effect of ketamine Neurology. 40:1990;1399-1403.
30. Schumer RA, Podos SM The nerve of glaucoma! Arch Ophthalmol. 112:1994;37-44.
31. Shohami E, Novikov M, Mechoulam R A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effect after closed head injury in the rat. J Neurotrauma. 10:1993;109-119.
32. Siesjo BK Mechanisms of ischemic brain damage. Crit Care Med. 16:1988;954-963.
33. Sommer A, Katz J, Quigley HAet al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 109:1991;77-83.
34. Sommer A, Tielsch JM, Katz Jet al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. Arch Ophthalmol. 109:1991;1090-1095.
35. Stys PK, Ransom BR, Waxman SG Compound action potential of nerve recorded by suction electrode. a theoretical and experimental analysis Brain Res. 546:1991;18-32.
36. Villegas-Prez MP, Vidal-Sanz M, Rasmunsky Met al. Rapid and protracted phases of retinal ganglion cell loss follows axotomy in the optic nerve of adult rat. J Neurobiol. 24:1993;23-36.
37. Yoles E, Belkin M, Schwartz M HU-211, a nonpsychotropic cannabinoid, produces a short- and long-term neuroprotection after optic nerve axotomy. J Neurotrauma. 13:1996;49-57.
38. Yoles E, Muller S, Schwartz M: NMDA-receptor antagonist acts as a survival factor in partially lesioned optic nerve: Implications for glaucoma therapy (submitted).
39. 1 reduces early injury-induced metabolic deficits and subsequent degeneration in the rat optic nerve. Invest Ophthalmol Vis Sci. 83:1992;3586-3591.